Answers are grounded in this paper and cite their sources.
In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. This work suggests future avenues for investigating mechanisms of melanoma formation and resistance to PD-1 blockade. See related article by Tang et al., p. 4250
No takes yet. Share an insight, caveat, or question.
Shoushtari et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: